New York – October 16, 2026 -- Actinium Pharmaceuticals (NYSE American: ATNM) granted new CFO Matt David, M.D., options on 250,000 shares at $0.97 each, plus 250,000 restricted stock units (RSUs) and up to 75,000 milestone-based RSUs, as inducement for joining the company.

CFO package combines options, time-based RSUs and milestone awards

The October 14, 2026 grant gives Dr. David a non-qualified stock option with a ten-year term. The $0.97 exercise price equals Actinium's closing price on the NYSE American that day.